Global Liver Institute applauds U.S. Representative Nydia Velázquez (D-NY) for reintroducing this vital legislation to improve the lives of all people impacted by liver disease. GLI was proud to collaborate in the development of The Liver Illness, Visibility, Education and Research Act (LIVER Act), first introduced in 2018.
Global Liver Institute
GLOBAL LIVER INSTITUTE
Global Leaders Gather to Exchange Best Practices in Liver Health Policy
Global Liver Institute (GLI) convened esteemed global leaders for an event on the sidelines of the 77th World Health Assembly in Geneva, Switzerland, entitled “Together for Better Liver Health: Amplifying Best Practices Globally,” in partnership with the European Association for the Study of the Liver (EASL).
Exploring Viral Hepatitis: Types, Diagnosis, and Treatment
Viral hepatitis, a group of infections affecting the liver, has long been a global health concern. As the seventh leading cause of death worldwide it stands out as the only communicable disease with rising mortality.
A3 Builds Support for Liver Health Policy Priorities – Liver Health Policy Update
In the post-election work period, “must-do” program reauthorizations are expected to be considered. Lawmakers will be eyeing action on these health care policies and more during the “lame duck” session after the November elections and before the 118th Congress gavels out.
A Spotlight on Rare Maternal Health – Pediatric & Rare Liver Diseases News
In April, GLI Program Director Kristin Hatcher was invited to engage with patient advocacy groups, industry partners, and patients during the PBC Foundation’s International Summit in Edinburgh, Scotland.
How does sleep affect fatty liver disease? – NASH News
At the Academy of Managed Care Pharmacy meeting on April 16, experts discussed the emerging landscape of NASH treatments, focusing on the recent approval of Madrigal’s Rezdiffra.
Global Liver Institute Thanks Senator Bill Cassidy for His Leadership in Fatty Liver Disease Research
GLI applauds the announcement of a federally-funded study by the Agency for Healthcare Research and Quality (AHRQ) to assess the prevalence of fatty liver disease (known as metabolic-associated fatty liver disease or nonalcoholic fatty liver disease) as well as its associated costs and barriers in the US.
Early-onset cancer rates rates are increasing globally – Liver Cancer News
We extend our deepest gratitude to Dr. Jennifer Guy, Dr. Anjana Pillai, Dr. Christopher Rose, Dr. Elliot Tapper, patient advocate Bruce Dimming, and our sponsors. In case you missed it, our webinar ‘Liver Cancer Care: Management of Hepatic Encephalopathy, Ascites, and Portal Hypertension’ is available on GLI’s YouTube channel! Whether you’re a patient, caregiver, or healthcare professional, this webinar offers guidance and education to improve liver care.
Global Liver Institute Statement on the Passing of Dr. Stephen Harrison
The entire field of liver health has experienced an incredible loss. It is with great sadness that Global Liver Institute, our Liver Action Network members and the patient community express our deepest sorrow on the sudden passing of Dr Stephen Harrison. Our condolences and prayers are with Dr. Harrison’s family, friends and loved ones.
Addressing Disparities in Organ Transplantation: A Call for Equitable Healthcare
Organ transplantation has revolutionized modern medicine, offering a beacon of hope for individuals battling end-stage organ failure. At the same time, it is intricately entwined with legal and policy frameworks governing procurement, allocation, and ethical considerations. From national regulations to international collaborations, addressing healthcare disparities and combating systemic injustices are vital to providing equal access to lifesaving procedures.
Congress begins Fiscal Year 2025 appropriations process and the Administration approves new treatments improving the lives of liver disease patients.
After a brief weekend shutdown, Congress passed the FY 2024 appropriations bills and President Joe Biden signed the $1.2 trillion government funding package on March 23, 2024, closing the books on fiscal year (FY) 2024 appropriations.
Celebrating the benefits of drug repurposing for pediatric rare liver disease patients – Pediatric & Rare Liver Diseases News
Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).